

REMARKS

In this Preliminary Amendment, the claims have been amended to conform with the issued claims in related U.S. Patent No. 7,078,165.

Claims 1-34 have been cancelled. Claims 35-49 are new.

Support for new claims 35-49 can be found throughout the specification, for example, as follows:

<u>Claim</u>	<u>Support</u>
35	Original claim 15; page 3, lines 24-28; page 4, lines 7-14; page 4, lines 18-24; page 8, line 29 - page 9, line 3; page 25, line 28 - page 26, line 5; Figure 5a
36	Original claim 15; page 3, lines 24-28; page 4, lines 7-14; page 4, lines 18-24; page 8, line 29 - page 9, line 3; page 25, line 28 - page 26, line 5; Figure 5a
37	Original claim 15; page 3, lines 24-28; page 4, lines 7-14; page 4, lines 18-24; page 8, line 29 - page 9, line 3; page 25, line 28 - page 26, line 5; Figure 5a
38	Original claim 15; page 3, lines 24-28; page 4, lines 7-14; page 4, lines 18-24; page 25, line 28 - page 26, line 5; Figure 5a
39	Original claims 11-13 and 16; page 4, lines 7-14; page 8, line 29 - page 9, line 3
40	Original claims 11-13 and 16; page 4, lines 7-14; page 8, line 29 - page 9, line 3
41	Original claims 11-13 and 16; page 4, lines 7-14; page 8, line 29 - page 9, line 3
42	Original claim 18; page 4, lines 28-31
43	Original claim 18; page 4, lines 28-31

<u>Claim</u>	<u>Support</u>
--------------	----------------

44	Original claims 11-13 and 18; page 4, lines 28-31
45	Original claims 11-13 and 18; page 4, lines 28-31
46	Original claims 11-13 and 18; page 4, lines 28-31
47	Original claims 11-13 and 18; page 4, lines 28-31
48	Original claims 11-13 and 18; page 4, lines 28-31
49	Original claim 17; page 4, lines 25-27

Applicant submits that these claim amendments are fully supported by the specification, do not introduce new matter or require a further search of the art, and respectfully request their entry.

In a Response to Restriction Requirement filed December 12, 2007, Applicant elected Group IV, drawn to a method for enhancing the immune response of a host, with traverse. Applicant also elected to prosecute the species L-Ala-D-Glu-mesoDAP, without traverse.

Applicant contended that there is unity of invention among Group IV (drawn to a method for enhancing the immune response of a host comprising administering an antigen and a molecule related to MTP and compositions thereof), Group V (a method for providing an immune response in a host comprising administering a molecule related to MTP and compositions thereof), and Group VI (drawn to method of vaccination comprising administering a molecule related to MTP and compositions thereof),

because all of the claims in these groups are directed to the use of a molecule related to muramyl tripeptide (MTP) to induce an immune response.

Applicant respectfully submits that new claims 35-38 belong to elected Group IV, new claims 39-43 belong to Group V, and new claims 44-49 belong to Group VI. The elected species reads on each of claims 35-49.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

William B. Reich

Dated: January 23, 2008

By: *William B. Reich* Reg. No. 54,386

Kenneth J. Meyers

for: Reg. No. 25,146

Phone: 202-408-4033

Fax: 202-408-4400

E-mail: ken.meyers@finnegan.com